• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SERPINE1 Gene Record

  • Summary
  • Interactions
  • Claims
  • SERPINE1 5054 Druggable Genome

    Alternate Names:

    5054
    SERPIN FAMILY E MEMBER 1
    SERPINE1
    PAI
    PAI-1
    PAI1
    PLANH1
    173360
    8583
    ENSG00000106366
    OTTHUMG00000157107
    Endothelial plasminogen activator inhibitor
    Serpin E1
    Plasminogen activator inhibitor 1
    P05121
    PA261
    PLASMINOGEN ACTIVATOR INHIBITOR-1 PRECURSOR (PAI-1) (ENDOTHELIAL PLASMINOGEN ACTIVATOR INHIBITOR) (PAI). [SOURCE:UNIPROT/SWISSPROT;ACC:P05121]
    PAI1_HUMAN
    T15556

    Gene Info:

    Target Class Miscellaneous
    Target Subclass Protease_inhib_Serpin family
    Human Readable Name PROTEASE INHIBITOR
    Human Readable Name DRUGGABLE GENOME
    Interpro Name Serpin family
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Family
    Interpro Acc IPR000215
    Uniprot Status Swiss-Prot
    Interpro Short Name Serpin_fam
    Gene Biotype PROTEIN_CODING
    (7 More Sources)

    Gene Categories: Category Details

    PROTEASE INHIBITOR
    DRUGGABLE GENOME

    Publications:

    Kaleelrahman et al., 2003, Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF)., Hematology
    Chadarevian et al., 2005, Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism., J. Endocrinol. Invest.
    Tsai SJ et al., 2008, Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response., Pharmacogenet Genomics
    Dondi et al., 2006, GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system., Oncol. Rep.
    Gerstein et al., 2003, [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]., Vopr Onkol
    Hellgren, 2003, Hemostasis during normal pregnancy and puerperium., Semin. Thromb. Hemost.
    Gamberi et al., Identification of markers of possible prognostic value in 57 giant cell tumors of bone., Oncol. Rep.
    Chang et al., Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells., Cell Commun. Adhes.
    Shetty et al., 2003, Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells., J. Biol. Chem.
    Hamilton et al., 1993, Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes., Blood
    French D et al., 2008, A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group., Blood
    Pedersen et al., 1995, Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease., Thromb. Haemost.
    Gorlatova NV et al., 2007, Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor., J Biol Chem
    Roos et al., 2001, Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage., Stroke
    Shafiq et al., 2006, A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study., Pharmacology
    Katz et al., 1996, Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors., Am. J. Cardiol.
    Rissanen et al., 2001, Weight change and blood coagulability and fibrinolysis in healthy obese women., Int. J. Obes. Relat. Metab. Disord.
    Moriyama et al., 1997, Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction., Jpn. Circ. J.
    Bouchie et al., 2000, P2Y receptor regulation of PAI-1 expression in vascular smooth muscle cells., Arterioscler. Thromb. Vasc. Biol.
    Sawathiparnich et al., 2002, Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans., J. Clin. Endocrinol. Metab.
    Demirkan et al., 2006, The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer., Clin. Appl. Thromb. Hemost.
  • TIPLASININ   SERPINE1

    Interaction Score: 6.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17276980


    Sources:
    DTC

  • DIAPLASININ   SERPINE1

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PREMARIN   SERPINE1

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8888658


    Sources:
    NCI

  • DALTEPARIN   SERPINE1

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17057417


    Sources:
    NCI

  • ALEPLASININ   SERPINE1

    Interaction Score: 3.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Plasminogen activator inhibitor-1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • UROKINASE   SERPINE1

    Interaction Score: 3.09

    Interaction Types & Directionality:
    inducer (activating)
    substrate

    Interaction Info:
    Trial Name urokinase for injection,Kinlytic
    Novel drug target Established target

    PMIDs:
    12785198 12709915 12579271 12745435 12642587


    Sources:
    TdgClinicalTrial

  • DEFIBROTIDE   SERPINE1

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12745658


    Sources:
    NCI

  • CETRORELIX   SERPINE1

    Interaction Score: 2.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16391860


    Sources:
    NCI

  • URIDINE   SERPINE1

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10712415


    Sources:
    NCI

  • ORLISTAT   SERPINE1

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11410822


    Sources:
    NCI

  • LEVOTHYROXINE   SERPINE1

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16075920


    Sources:
    NCI

  • CAPTOPRIL   SERPINE1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9152782


    Sources:
    NCI

  • NIMODIPINE   SERPINE1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11486117


    Sources:
    NCI

  • REGRAMOSTIM   SERPINE1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8260700


    Sources:
    NCI

  • VASOPRESSIN   SERPINE1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7482412


    Sources:
    NCI

  • FLUOXETINE   SERPINE1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18794724


    Sources:
    PharmGKB

  • EPIRUBICIN   SERPINE1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16444429


    Sources:
    NCI

  • CITALOPRAM   SERPINE1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18794724


    Sources:
    PharmGKB

  • HYDROCHLOROTHIAZIDE   SERPINE1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11836266


    Sources:
    NCI

  • DEXAMETHASONE   SERPINE1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18285546


    Sources:
    PharmGKB

  • Ensembl: ENSG00000106366

    • Version: 101_38

    Alternate Names:
    SERPINE1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P05121

    • Version: January-2014

    Alternate Names:
    SERPINE1 Gene Symbol

    Gene Info:
    Target Class Miscellaneous
    Target Subclass Protease_inhib_Serpin family

    Publications:

  • HopkinsGroom: P05121

    • Version: 11-September-2012

    Alternate Names:
    5054 Entrez Gene Id
    PAI1_HUMAN Uniprot Id
    PLASMINOGEN ACTIVATOR INHIBITOR 1 Uniprot Protein Name

    Gene Info:
    Human Readable Name DRUGGABLE GENOME
    Interpro Name Serpin family
    Human Readable Name PROTEASE INHIBITOR

    Gene Categories:
    PROTEASE INHIBITOR, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000106366

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000106366 Ensembl Gene Id
    SERPINE1 Display Id
    PLASMINOGEN ACTIVATOR INHIBITOR-1 PRECURSOR (PAI-1) (ENDOTHELIAL PLASMINOGEN ACTIVATOR INHIBITOR) (PAI). [SOURCE:UNIPROT/SWISSPROT;ACC:P05121] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: SERPINE1

    • Version: 18-August-2020

    Alternate Names:
    PA261 PharmGKB ID

    Gene Info:

    Publications:
    Tsai SJ et al., 2008, Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response., Pharmacogenet Genomics
    French D et al., 2008, A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group., Blood

  • NCI: SERPINE1

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Kaleelrahman et al., 2003, Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF)., Hematology
    Roos et al., 2001, Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage., Stroke
    Sawathiparnich et al., 2002, Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans., J. Clin. Endocrinol. Metab.

  • DTC: SERPINE1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Gorlatova NV et al., 2007, Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor., J Biol Chem

  • HingoraniCasas: ENSG00000106366

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000106366 Gene Symbol
    SERPINE1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: PAI1

    • Version: chembl_23

    Alternate Names:
    PLANH1 GENE_SYMBOL
    SERPINE1 GENE_SYMBOL
    Plasminogen activator inhibitor 1 UNIPROT

    Gene Info:

    Publications:

  • dGene: SERPINE1

    • Version: 27-Jun-2013

    Alternate Names:
    5054 Gene ID
    PAI dGene Synonym
    PAI-1 dGene Synonym

    Gene Info:

    Gene Categories:
    PROTEASE INHIBITOR

    Publications:

  • TTD: Endothelial plasminogen activator inhibitor

    • Version: 2020.06.01

    Alternate Names:
    SERPINE1 TTD Gene Abbreviation
    T15556 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21